Abstract accepted at EHA2023 outlining the results of an interim analysis of an ongoing study evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Abstract accepted at EHA2023 presenting an updated analysis of a Phase 2 study evaluating the efficacy and safety of a BTKi in combination with an anti-CD20 monoclonal antibody in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Abstract accepted at EHA2023 presenting the final analysis of a Phase 2 study evaluating the efficacy and safety of BTK inhibition in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Chat with BeiGene

Close